Bone Mineral Homeostasis Drugs Flashcards
cholecalciferol
vit D3
ergocalciferol
Vit D2
raloxifene
selective estrogen-receptor modulator
alendronate
bisphosphanate
denosumab
prolia
RANKL
binds RANK - induces osteoclast formation
Ca and P balance
renal excretion balances intestinal absorption
PTH
increased serum Ca
decreased serum PO4
acts on osteoblasts to produce RANKL
-increased osteoclast activity - bone remodeling
PTH in kidney
increased Ca absorption
decreased PO4 absorption
teriparatide
synthetic parathyroid hormone
teriparatide
intermittent - once daily subQ - promotes bone grwoth
teriparatide CI
patient at risk for osteosarcoma
calcitriol
1,25 Vit D
calcitriol on kidney
increased absorption of Ca and PO4
tx of rickets
Vit D analogs
patient with liver disease
should use 25 Vit D
patient with kieny disease
should use 1,25 Vit D
calcitriol risk
hypercalcemia
adverse drug effects of vit D analogs
arrhythmia and pancreatitis
FGF23
inhibits 1,25 Vit D production
inhibits PO4 reabsorption in kidney
Vit D and Ca and PO4
increases both levels in serum
PTH and Ca and PO4
serum calcium increased
serum phosphate decreased
calcitonin
from C cells of thyroid
decrease serum Ca and PO4
inhibits osteoclast activity
decreases Ca and PO4 reabsorption
tx of pagets
calcitonin
glucocorticoids
decrease total body calcium stores
raloxifene
selective serotonin receptor modulator (SERM)
tx for post-menopausal osteoporosis
partial agonist at bone but does not stimulate endometrial proliferation
estrogens
reduce bone resorbing actions of PTH
ADRs of estrogens
hot flashes, leg cramps, thromboembolism
bisphosphonate MOA
analog of pyrophosphate in which P-O-P bond replaced with non-hydrolyzable P-C-P bond
-cheoate Ca
concentrate at sites of active bone remodeling - incorporated into bone
decreased osteoclast activity
when to take bisphosphonates
on empty stomach
ADR bisphosphonate
erosive esophagitis
osteonecrosis of jaw
denosumab MOA
monoclonal Ab - binds and prevents action of RANKL
blocks osteoclast activation
denosumab use
tx of post-menopausal osteoporosis and cancers (prostate and breast)
ADRs denosumab
increased risk of infection
osteonecrosis of jaw
transient hpocalcemia
thiazide therapy
can cause hyperCa
tx of hypercalcemia
saline diuresis with or without furosemide
bisphosphonates
calcitonin
phosphate (to decrease serum Ca)
glucocorticoids
tx of hypocalcemia
calcium IV, IM, or PO
thyrotoxicosis
osteoporosis
first line for pagets
calcitonin
bisphosphonates
post menopausal osteoporosis estrogen use
concern for increased risk of breast cancer and fails to reduce heart disease
IV calcium
calcium gluconate
-less irritating to veins
oral calcium
calcium carbonate preferred
high % of calcium